Can we ever observe newly diagnosed chronic phase CML patients and not immediately start them on therapy?  

if so, are there specific cytogenetic, molecular, clinical, or hematologic factors that you take into consideration?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice